William Blair analyst Raju Prasad maintained a Hold rating on Alexion Pharmaceuticals (ALXN – Research Report) today. The company’s shares closed last Tuesday at $182.50, close to its 52-week high of $187.45.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 12.0% and a 50.0% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Crispr Therapeutics AG, and Rocket Pharmaceuticals.
Currently, the analyst consensus on Alexion Pharmaceuticals is a Hold with an average price target of $183.60.
See today’s analyst top recommended stocks >>
The company has a one-year high of $187.45 and a one-year low of $99.91. Currently, Alexion Pharmaceuticals has an average volume of 3.96M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on developing life-transforming drugs that are used for treating patients with ultra-rare diseases and disorders.
Read More on ALXN: